These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Secondary hyperparathyroidism: incidence, clinical presentations, treatment].
    Author: Samokhvalova NA, Romanchishen AF, Gerasimchuk RP, Grinev KM, Zemchenkov AIu.
    Journal: Vestn Khir Im I I Grek; 2007; 166(5):78-81. PubMed ID: 18154100.
    Abstract:
    Prevalence of secondary hyperparathyroidism (SHPT) was studied in 235 patients treated by program hemodialysis. SHPT was diagnosed according to recommendations of K/DOQI Clinical Practice Guidelines with the parathyroid hormone (PTH) level higher than 300 pg/ml. In the beginning of replacement renal therapy with hemodialysis the secondary hyperparathyroidism of different degree was found in 145 patients (61.7%): mild form (PTH from 300 to 450 pg/ml) in 37.8%, medium (PTH from 450 to 1000 pg/ml) in 40.5%, severe (PTH more than 1000 pg/ml) in 21.7%. Normal indices of PTH were determined in 70 patients. In 20 patients the parathyroid hormone was less than 120 pg/ml and they had symptoms of adynamic disease of the bones. In the group of patients observed for 4 years (n = 80) the incidence of SHPT became less against the background of treatment from 60.0% to 37.0%. Relatively satisfactory results of conservative treatment can be explained by predominance of patients with less than 5 years of CRF. The therapy was more effective in patients with mild and medium forms of SHPT. In patients with severe SHPT (PTH more than 1000 pg/ml) the effect was partial and 77.0% of these patients needed surgical treatment.
    [Abstract] [Full Text] [Related] [New Search]